Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2021 - 2025)

Kiniksa Pharmaceuticals International's Share-based Compensation history spans 5 years, with the latest figure at $10.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 23.34% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $37.0 million, up 20.56%, while the annual FY2025 figure was $37.0 million, 20.56% up from the prior year.
  • Share-based Compensation reached $10.2 million in Q4 2025 per KNSA's latest filing, up from $10.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q4 2025 to a low of $5.7 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.0 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: decreased 15.37% in 2022, then rose 29.62% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.1 million in 2021, then grew by 3.93% to $6.4 million in 2022, then grew by 21.99% to $7.8 million in 2023, then increased by 6.75% to $8.3 million in 2024, then grew by 23.34% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Share-based Compensation are $10.2 million (Q4 2025), $10.1 million (Q3 2025), and $8.9 million (Q2 2025).